Baxfendy (Baxdrostat): Novel Aldosterone Synthase Inhibitor for Resistant Hypertension
Baxfendy (baxdrostat) is a first-in-class, highly selective aldosterone synthase inhibitor FDA-approved in May 2026 for treating hypertension in combination with other antihypertensive drugs in adults whose blood pressure remains inadequately controlled on other agents. 1, 2
Mechanism of Action
Baxdrostat works by selectively inhibiting aldosterone synthase, the enzyme responsible for aldosterone production, without affecting cortisol synthesis. This targeted mechanism directly addresses aldosterone dysregulation, which is a major contributor to resistant and hard-to-control hypertension 3, 2. This distinguishes it from mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone, which block aldosterone's effects rather than its production.
Clinical Efficacy
Blood Pressure Reduction
The evidence for baxdrostat's efficacy is robust and consistent across multiple high-quality trials:
In resistant hypertension (patients on ≥3 antihypertensives including a diuretic), baxdrostat 2 mg reduced 24-hour ambulatory systolic BP by -14.0 mm Hg compared to placebo (p<0.0001) 4
In uncontrolled/resistant hypertension, seated systolic BP was reduced by -8.7 mm Hg with 1 mg and -9.8 mm Hg with 2 mg compared to placebo (both p<0.001) 5
Meta-analyses confirm these findings, showing systolic BP reductions of -6.25 to -8.93 mm Hg and diastolic BP reductions of -2.92 to -3.79 mm Hg 6, 7, 8
Dose-Response Relationship
A clear linear dose-response exists: each 1 mg increase in baxdrostat dose reduces seated systolic BP by approximately 3.3 mm Hg 7. Both 1 mg and 2 mg doses effectively lower BP, but the 2 mg dose shows superior efficacy in achieving BP control targets (<130 mm Hg systolic) 7.
BP Control Rates
Baxdrostat significantly increases the proportion of patients achieving target BP control (<130 mm Hg systolic), with a 2.08-fold higher likelihood compared to placebo 6.
Indications and Usage
Baxfendy is indicated for hypertension treatment in combination with other antihypertensive drugs to lower blood pressure in adults not adequately controlled on other agents 1. The most recent ESC guidelines (2024) specifically mention baxdrostat as a newer agent being tested for treating primary aldosteronism and resistant hypertension 3.
Clinical Context
This medication addresses a critical unmet need. Current guidelines recommend multiple drug combinations for resistant hypertension 3, 9, 3, but many patients remain uncontrolled. Baxdrostat provides an additional mechanistic approach by directly targeting aldosterone excess, which is particularly relevant since primary aldosteronism is the most common form of secondary hypertension 3.
Dosing and Administration
- Take 1 tablet orally once daily 1
- Can be taken with or without food 1
- Swallow tablets whole—do not cut, crush, or chew 1
- Available doses: 1 mg and 2 mg (based on trial data) 5
- If a dose is missed, take the next dose at the regularly scheduled time; do not double dose 1
Safety Profile and Adverse Effects
Primary Safety Concerns
The most significant adverse effect is hyperkalemia (elevated potassium levels). This risk is substantially increased compared to placebo:
- Potassium >6.0 mmol/L occurred in 2.3-3.0% of baxdrostat patients vs. 0.4% with placebo 5
- Meta-analyses show a 5.59 to 10.22-fold increased risk of hyperkalemia 6, 7
- Overall hyperkalemia risk (K+ ≥5.5 mmol/L) increased 2.87-fold 10
Other Electrolyte Disturbances
- Hyponatremia (low sodium) risk increased 2.90-fold 6
- Serum sodium decreased (standardized mean difference: -0.63) 6
- Modest decline in eGFR observed (standardized mean difference: -0.49) 6
Overall Tolerability
- Overall adverse events increased modestly (RR: 1.24) 6
- Serious adverse events and mortality were NOT significantly different from placebo 6, 10
- Most hyperkalemia cases were mild and manageable 10
Monitoring Requirements
Your healthcare provider will check potassium and sodium levels before starting Baxfendy and periodically during treatment 1. Treatment may be temporarily stopped if high potassium or low sodium develops 1.
High-Risk Populations for Hyperkalemia
Risk is increased if you:
- Are ≥65 years of age
- Have diabetes
- Have kidney problems
- Take other medicines that increase potassium (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics) 1
Talk to your healthcare provider before using potassium supplements or salt substitutes containing potassium 1.
Contraindications and Precautions
Before Taking Baxfendy, Inform Your Provider If You Have:
- High potassium levels in blood
- Kidney problems
- Diabetes
- Pregnancy or plans to become pregnant (safety unknown in pregnancy)
- Breastfeeding or plans to breastfeed (unknown if drug passes into breast milk) 1
Not Recommended For:
- Children under 18 years (safety and efficacy not established) 1
Clinical Positioning
Baxfendy represents a mechanistically distinct option for patients with resistant hypertension who remain uncontrolled despite guideline-directed therapy. Current guidelines emphasize that resistant hypertension should be treated with combinations of first-line agents (thiazide/thiazide-like diuretics, ACE inhibitors, ARBs, and long-acting calcium channel blockers) 3, 9, 3, 11. When these fail, baxdrostat offers an alternative that directly addresses aldosterone excess.
Advantages Over MRAs
Unlike spironolactone (which causes gynaecomastia and erectile dysfunction) or eplerenone (which requires twice-daily dosing and is less potent), baxdrostat is:
- Highly selective for aldosterone synthase
- Cortisol-sparing (doesn't affect cortisol production)
- Once-daily dosing
- Potentially better tolerated regarding hormonal side effects 3, 10
Storage
- Store at room temperature 68°F to 77°F (20°C to 25°C)
- Keep in original bottle with desiccant packet (do not discard)
- Bottle has child-resistant closure—keep out of reach of children 1
Evidence Quality
The evidence supporting baxdrostat is high to moderate certainty based on GRADE assessment 6, 10. The trials were well-designed, double-blind RCTs with consistent results across multiple studies. The primary limitation is the relatively short duration of available trials (12 weeks), highlighting the need for long-term cardiovascular outcome studies 6, 8.